HLOSFOTCHealthcare · Biotechnology

Healios K.K.

$2.20+0.00%(+$0.00)

TickerSpark Score

44/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLOSF research report →

52-Week Range12% of range

Low $1.90

Current $2.20

High $4.45

Companywww.healios.co.jp

Healios K. K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.

CEO: Tadahisa S. Kagimoto
IPO: 2020
Employees: 65
HQ: Tokyo, JP

Price Chart

-2.22% · this period

Valuation

Market Cap: $236.85M
P/E: -12.88
P/S: 467.01
P/B: 5.35
EV/EBITDA: -13.74
Div Yield: 0.00%

Profitability

Gross Margin: -529.73%
Op Margin: -5113.51%
Net Margin: -4235.14%
ROE: -75.40%
ROIC: -20.69%

Growth & Income

Revenue: $104.09M · -81.41%
Net Income: $-2,218,934,580 · 47.60%
EPS: $-20.39 · 57.41%
Op Income: $-3,405,969,498
FCF YoY: -57.06%

Performance & Tape

52W High: $4.45
52W Low: $1.90
50D MA: $2.37
200D MA: $2.87
Beta: 0.50
Avg Volume: 25

Get TickerSpark's AI analysis on HLOSF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime